Market Competitors Reshape Obesity Pharmacotherapy
Novo Nordisk is way ahead in the race for weight-loss pills. The company rolled out its pill version of Wegovy in January 2026, and by June it had already crossed three million prescriptions. That’s one of the strongest launches any new drug has ever had.
Here’s the interesting part: more than 80% of people getting the prescription had never tried a weight-loss drug before. That tells us something important the pill isn’t just pulling patients away from the injection. It’s bringing in a whole new group of people who wouldn’t have tried treatment otherwise.
In April 2026, the FDA approved a competing pill from Eli Lilly, sold under the name Foundayo. Its active ingredient, orforglipron, works a bit differently than semaglutide (the ingredient in Wegovy). Instead of being a peptide, it’s a small molecule, a real shift in how these drugs are built.
Even so, Wegovy still holds most of the market with about 89% of oral prescriptions in this category. A few reasons explain that gap. Wegovy has years of brand trust behind it from its injectable version, so people already know the name. Doctors also tend to stick with what they know, and semaglutide has a longer track record than this newer molecule.
On top of that, Wegovy’s pill showed slightly better results in late-stage trials. That said, the two drugs were never tested head-to-head, so it’s hard to say for sure which works better. We’ll likely get clearer answers as more real-world data comes in.
Foundayo does have one clear advantage you can take it any time of day, with or without food or water. Wegovy’s pill comes with stricter rules around fasting, which some patients find hard to stick to. For anyone who struggles with rigid schedules, that flexibility could be a big draw.
One thing to know: Foundayo carries a warning about a possible risk of thyroid tumors. This isn’t unique to Foundayo it’s a standard warning for this entire class of drugs, so doctors already know to watch for it.
Eli Lilly is also trying to make Foundayo cheaper to get. People with qualifying insurance can pay a low monthly price through savings cards, and those paying out of pocket have pricing based on their dose. Medicare patients recently got access to lower-cost options too.
This fits a bigger trend in the industry: drug makers are finally trying to fix the affordability problem that’s kept many patients away, despite how much they could benefit from treatment. Lower prices could help these drugs reach a much wider range of people.
Right now, Foundayo is only approved for weight management in adults. But Eli Lilly is running more trials to see if it also works for type 2 diabetes. If those trials go well, the company could apply to expand what the drug is approved for which would open it up to a much bigger group of patients and put it in even more direct competition with semaglutide.
That kind of regulatory review usually takes several months, so we won’t know the outcome anytime soon. Both companies are chasing the same prize: people who’ve avoided treatment because they didn’t want injections. As these pills mature, the real test will come down to which one delivers better long-term results along with which one insurance covers more easily and which one doctors feel most comfortable prescribing.
